Atopische Erkrankungen - Arzneimittelexantheme - stetige Zunahme in Industrieländern

Zusammenfassung

Das Arzneimittelexanthem zeichnet sich durch eine nahezu unbegrenzte morphologische Vielfalt aus und zählt zu den häufigsten dermatologischen Krankheitsbildern. In zirka 5 % aller stationären Behandlungen führt eine Arzneimittelnebenwirkung zur Aufnahme. Der jährlich steigende Medikamentenkonsum in Deutschland, in Kombination mit den ständig neu auf den Markt kommenden Medikamenten der pharmazeutischen Industrie, erklären die sprunghafte Zunahme der Inzidenz von Arzneimittelexanthemen in den letzten Jahren.

Summary

Drug-related exanthema is characterised by virtually unlimited morphological variety, and is one of the most common dermatological pathologies. Roughly 5 % of all hospitalisations are due to the side effects of medication. The rapid increase in the incidence of drug-related exanthema may be explained by the annual increase in medication consumption in Germany, together with the constant stream of new drugs being brought onto the market by the pharmaceutical industry.

Literatur

• 1 Auquier-Dunant A, Mockenhaupt M, Naldi L. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.  Arch Dermatol. 2002;  138 1019-1024
• 2 Babu KS, Belgi G. Management of cutaneous drug reactions.  Curr Allergy Asthma Rep. 2002;  2 26-33
• 3 Bachot N, Roujeau JC. Physiopathology and treatment of severe drug eruptions.  Curr Opin Allergy Clin Immunol. 2001;  1 293-298
• 4 Bigby M. Incidence, prevalence and the rates of cutaneous reactions to drugs.  J Eur Acad Dermatol Venereol. 2000;  14 435
• 5 Bigby M. Rates of cutaneous reactions to drugs.  Arch Dermatol. 2001;  137 765-770
• 6 Breathnach SM. Adverse cutaneous reactions to drugs.  Clin Med. 2002;  2 15-19
• 7 Del Rosso JQ. Skin manifestations of drug reactions.  Curr Allergy Asthma Rep. 2002;  2 282-287
• 8 Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience.  Drug Saf. 2002;  25 965-972
• 9 Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.  Am J Clin Dermatol. 2000;  1 349-360
• 10 Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome.  Dermatol Online J. 2002;  8 5
• 11 Revuz J. New advances in severe adverse drug reactions.  Dermatol Clin. 2001 Oct. 19;  697-709
• 12 Sullivan JR, Shear NH. Drug eruptions and other adverse drug effects in aged skin.  Clin Geriatr Med. 2002;  18 21-42
• 13 Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions.  Pharmacol Rev. 2001;  53 357-379
• 14 Ward HA, Russo GG, Shrum J. Cutaneous manifestations of antiretroviral therapy.  J Am Acad Dermatol. 2002;  46 284-293
• 15 Warnock JK, Morris DW. Adverse cutaneous reactions to antipsychotics.  Am J Clin Dermatol. 2002;  3 629-636

Anschrift für die Verfasser